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Corrections 2327Kir2.1, was alone sufficient to significantly reduce co-immunoprecipitation of MBP-SUR2A(1294-1358) by ~50 %
(P<0.0009) and ~80% (P<0.0001), respectively. Similarly, co-immunoprecipitation with Kir6.2 of chimaeras of
SUR2A(1294-1358) containing multi-drug resistance protein-1 (MRP1) sequence further refined the SUR2A binding motif
to residues 1318-1337. Mutagenesis of charged residues in SUR2A, E1318R, K1322D and Q1336E, conserved in SUR1 but
not MRP1, reduced co-immunoprecipitation. Whole cell patch clamp of Kir6.2(K338E)/SUR2AWT channels 48-72 h after
transfection in HEK 293 cells revealed increased sensitivity to agonist, pinacidil (EC50 ¼ 4.55 0.3 versus 39.65 13 mM
with Kir6.2-WT), and reduced sensitivity to antagonist, glibenclamide (IC50 ¼ 103 5 28 versus 3.1 5 0.8 nM with
Kir6.2-WT). Expression of the double mutant Kir6.2(K338E)/SUR2A(E1318R) restored wild-type properties (EC50 pinaci-
dil ¼ 46.7 5 4.9 mM; IC50 glibenclamide ¼ 6.4 5 0.9 nM). Similar results were observed for the equivalent residue on
Kir6.1 (R347). Furthermore, inside-out patch clamp revealed that the IC50 for ATP was unaffected in Kir6.2K338E/
SUR2A channels (27.5 5 2.0 versus 23.8 5 1.7 mM with Kir6.2-WT, P>0.5).
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